PolyPid PYPD

NASDAQ PYPD

$5.20 -0.13 (-2.44%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap85.52 Mn

P/E2.72

Div. Yield0.00

Add ratio to table…

About

PolyPid Ltd. is an innovative biopharmaceutical company dedicated to improving patient outcomes by developing long-acting, controlled-release medicines that deliver therapy precisely at the site of care. The company’s core technology, PLEX, combines biocompatible polymer and lipid layers to create a protective reservoir that enables sustained release of active pharmaceutical agents over periods ranging from several days to several months. PolyPid applies this platform to address high unmet medical needs in surgical care, metabolic diseases, oncology, and other localized conditions. Its lead product candidate, D-PLEX 100, pairs PLEX with the FDA‑approved antibiotic doxycycline to prevent surgical site infections for up to 30 days. In addition, the company is advancing a long‑acting GLP‑1 receptor agonist delivery platform and an intra‑tumoral oncology candidate, OncoPLEX, leveraging the same PLEX foundation.

PolyPid Ltd. has not yet commercialized a product and therefore does not generate revenue from product sales. Its current revenue stems from licensing agreements, collaborative research arrangements, and potential milestone payments. In August 2022 the company entered into an exclusive license, distribution and supply agreement with Advanz for the EEA and the United Kingdom, granting Advanz the right to market, promote and sell D-PLEX 100 for prevention of post‑abdominal and post‑cardiac surgical infections. The agreement may provide PolyPid with upfront fees, royalties on net sales and milestone payments tied to regulatory and commercial achievements. Additionally, PolyPid has entered into research collaborations, such as the December 2024 partnership with ImmunoGenesis to combine PLEX technology with a STING agonist for solid‑tumor oncology programs. These collaborations typically involve upfront payments, research funding and future milestones. Until D-PLEX 100 or another candidate receives regulatory approval, the company’s revenue will remain primarily partnership‑driven.

PolyPid Ltd. occupies a niche within the biopharmaceutical industry as a developer of localized drug‑delivery systems that overcome the limitations of systemic administration. Its PLEX technology differentiates it from competitors that rely on polymer‑only or lipid‑only matrices, which often suffer from burst release, short duration, or drug migration. Competitors in the surgical infection prevention space include manufacturers of antibiotic‑loaded bone cement (e.g., BoneSupport AB), triclosan‑coated sutures, negative‑pressure wound therapy devices, and resorbable gentamicin‑collagen sponges approved in Europe and Canada. PolyPid’s advantages stem from its proprietary polymer‑lipid architecture that provides constant, predictable release, protects the drug from degradation, anchors at the treatment site, and requires no chemical modification of the active agent. The company’s broad patent estate, Fast Track and Breakthrough Therapy designations for D‑PLEX 100, and its ability to pair PLEX with a wide variety of APIs further strengthen its competitive stance.

PolyPid Ltd.’s primary customers are hospitals and surgical centers that perform procedures with a high risk of surgical site infections, such as abdominal colorectal, cardiac, and orthopedic surgeries. Through its agreement with Advanz, the company indirectly serves healthcare providers across the European Economic Area and the United Kingdom who will administer D‑PLEX 100 to patients undergoing those procedures. In the United States, PolyPid intends to partner with large pharmaceutical companies that have established hospital‑focused commercial networks to bring D‑PLEX 100 to U. S. surgical facilities. Additionally, its research collaborations with entities like ImmunoGenesis indicate a customer base that includes biotechnology firms seeking to enhance the local delivery of novel therapeutics. Until commercial launch, the company’s revenue‑generating relationships are with these partners rather than with end‑patient consumers.

Investment Thesis

▲ Bull case

PolyPid is positioned to capitalize on a significant unmet need in surgical site infection prevention, with D-PLEX100 demonstrating a 64% relative risk reduction in clinically significant wound infections (asepsis score >20) in the SHIELD II trial, a result that directly addresses hospital priorities under Medicare’s TEAM model which financially penalizes institutions for 30-day postoperative complications. This clinical efficacy, combined with the product’s sustained 30-day doxycycline release profile, creates a compelling value proposition that aligns with both antimicrobial stewardship goals and evolving reimbursement structures, suggesting strong uptake potential upon commercial launch in Q1 2027 even without aggressive marketing spend, as hospital P&T committees and payers increasingly prioritize solutions that reduce systemic antibiotic use and associated costs.
The company’s strategic progress toward FDA approval is de-risking faster than market expectations, evidenced by the successful submission of CMC and nonclinical NDA modules, the $4.3 million PDUFA fee waiver preserving cash reserves, and proactive engagement with FDA through Breakthrough Therapy Designation channels to preemptively address regulatory concerns—actions that significantly increase the likelihood of a smooth pre-approval inspection and timely priority review, potentially shortening the FDA timeline to six months post-submission and bringing approval within reach by late 2026, well ahead of the guided Q1 2027 launch.
PolyPid’s balance sheet has been meaningfully strengthened through the full repayment of its outstanding debt facility in early May 2026, eliminating interest expense and leverage risks just as the company approaches critical regulatory and commercialization milestones, while existing cash resources of $10.9 million as of March 31, 2026—supplemented by warrant exercise proceeds and stringent operating expense control (R&D down to $5.8M QoQ)—are projected to fund operations through the second half of 2026 and key upcoming catalysts, reducing near-term financing pressure and allowing management to focus exclusively on execution rather than survival.
The U.S. strategic partnership discussions, described by management as being in their “late stages” with due diligence complete and definitive agreement terms under active negotiation, represent a near-term catalyst that remains underappreciated by the market; securing a partner with established hospital sales force capabilities would not only accelerate commercial launch but also validate the product’s market potential through third-party endorsement, potentially triggering a re-rating of the stock ahead of formal approval as investors anticipate revenue visibility and reduced commercialization risk.

PolyPid is positioned to capitalize on a significant unmet need in surgical site infection prevention, with D-PLEX100 demonstrating a 64% relative risk reduction in clinically significant wound infections (asepsis score >20) in the SHIELD II trial, a result that directly addresses hospital priorities under Medicare’s TEAM model which financially penalizes institutions for 30-day postoperative complications. This clinical efficacy, combined with the product’s sustained 30-day doxycycline release profile, creates a compelling value proposition that aligns with both antimicrobial stewardship goals and evolving reimbursement structures, suggesting strong uptake potential upon commercial launch in Q1 2027 even without aggressive marketing spend, as hospital P&T committees and payers increasingly prioritize solutions that reduce systemic antibiotic use and associated costs.
The company’s strategic progress toward FDA approval is de-risking faster than market expectations, evidenced by the successful submission of CMC and nonclinical NDA modules, the $4.3 million PDUFA fee waiver preserving cash reserves, and proactive engagement with FDA through Breakthrough Therapy Designation channels to preemptively address regulatory concerns—actions that significantly increase the likelihood of a smooth pre-approval inspection and timely priority review, potentially shortening the FDA timeline to six months post-submission and bringing approval within reach by late 2026, well ahead of the guided Q1 2027 launch.
PolyPid’s balance sheet has been meaningfully strengthened through the full repayment of its outstanding debt facility in early May 2026, eliminating interest expense and leverage risks just as the company approaches critical regulatory and commercialization milestones, while existing cash resources of $10.9 million as of March 31, 2026—supplemented by warrant exercise proceeds and stringent operating expense control (R&D down to $5.8M QoQ)—are projected to fund operations through the second half of 2026 and key upcoming catalysts, reducing near-term financing pressure and allowing management to focus exclusively on execution rather than survival.
The U.S. strategic partnership discussions, described by management as being in their “late stages” with due diligence complete and definitive agreement terms under active negotiation, represent a near-term catalyst that remains underappreciated by the market; securing a partner with established hospital sales force capabilities would not only accelerate commercial launch but also validate the product’s market potential through third-party endorsement, potentially triggering a re-rating of the stock ahead of formal approval as investors anticipate revenue visibility and reduced commercialization risk.

▼ Bear case

PolyPid’s financial runway remains perilously short despite recent debt repayment, with $10.9 million in cash as of March 31, 2026 insufficient to sustain operations through the second half of 2026 and critical milestones like FDA approval and partnership finalization without additional funding, as the company’s net loss of $7.7 million in Q1 2026 implies an annualized burn rate exceeding $30 million, meaning current cash would be depleted in under five months even at reduced spending levels, creating a high risk of dilutive financing or partnership terms heavily unfavorable to shareholders if approval timelines slip or negotiations stall.
The company’s overreliance on a single product candidate, D-PLEX100, for near-term value creation presents substantial binary risk, as any delay in the imminent completion of the NDA submission—particularly the clinical module—or failure to secure FDA acceptance due to unresolved CMC concerns related to its novel differentiated drug product could trigger a significant valuation reset, especially given the lack of meaningful pipeline diversification discussed in the earnings call, with expansion into other abdominal indications or metabolic health remaining early-stage and contingent on partnership execution that has not yet materialized.
Regulatory timelines in Europe are being underestimated, as PolyPid’s plan to submit the MAA to the EMA in Q3 2026 relies on alignment with Rapporteur and Co-Rapporteur that may not materialize given the complexity of the centralized procedure under therapeutic innovation pathways, and any delay beyond Q3 would push potential EU approval into 2028 or later, diminishing the perceived transformative potential of 2026 and eroding investor confidence in management’s ability to execute on dual-track regulatory strategy, particularly if FDA feedback reveals gaps requiring additional data that could stall both U.S. and European submissions.
The anticipated commercial benefits of D-PLEX100 under Medicare’s TEAM model are speculative and hospital adoption is far from guaranteed, as the company’s reliance on soft metrics like reduced wound severity and theoretical resource utilization savings lacks hard outcome data on actual cost reduction or readmission rates, and hospital P&T committees may remain hesitant to adopt a premium-priced product without clear formulary placement or proven budget impact, especially if reimbursement pathways under TEAM are still evolving and hospitals lack incentive to invest in prevention when penalties are tied to complications that may be underreported as noted by KOLs during the Surgical Infection Society roundtable.

PolyPid’s financial runway remains perilously short despite recent debt repayment, with $10.9 million in cash as of March 31, 2026 insufficient to sustain operations through the second half of 2026 and critical milestones like FDA approval and partnership finalization without additional funding, as the company’s net loss of $7.7 million in Q1 2026 implies an annualized burn rate exceeding $30 million, meaning current cash would be depleted in under five months even at reduced spending levels, creating a high risk of dilutive financing or partnership terms heavily unfavorable to shareholders if approval timelines slip or negotiations stall.
The company’s overreliance on a single product candidate, D-PLEX100, for near-term value creation presents substantial binary risk, as any delay in the imminent completion of the NDA submission—particularly the clinical module—or failure to secure FDA acceptance due to unresolved CMC concerns related to its novel differentiated drug product could trigger a significant valuation reset, especially given the lack of meaningful pipeline diversification discussed in the earnings call, with expansion into other abdominal indications or metabolic health remaining early-stage and contingent on partnership execution that has not yet materialized.
Regulatory timelines in Europe are being underestimated, as PolyPid’s plan to submit the MAA to the EMA in Q3 2026 relies on alignment with Rapporteur and Co-Rapporteur that may not materialize given the complexity of the centralized procedure under therapeutic innovation pathways, and any delay beyond Q3 would push potential EU approval into 2028 or later, diminishing the perceived transformative potential of 2026 and eroding investor confidence in management’s ability to execute on dual-track regulatory strategy, particularly if FDA feedback reveals gaps requiring additional data that could stall both U.S. and European submissions.
The anticipated commercial benefits of D-PLEX100 under Medicare’s TEAM model are speculative and hospital adoption is far from guaranteed, as the company’s reliance on soft metrics like reduced wound severity and theoretical resource utilization savings lacks hard outcome data on actual cost reduction or readmission rates, and hospital P&T committees may remain hesitant to adopt a premium-priced product without clear formulary placement or proven budget impact, especially if reimbursement pathways under TEAM are still evolving and hospitals lack incentive to invest in prevention when penalties are tied to complications that may be underreported as noted by KOLs during the Surgical Infection Society roundtable.

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	211.73 Bn	24.22	5.56	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	180.92 Bn	-62.49	5.94	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	132.16 Bn	30.00	10.50	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	82.89 Bn	19.15	5.34	1.99 Bn
5	ARGX	Argenx Se	primary	61.41 Bn	35.80	11.75	-
6	MRNA	Moderna, Inc.	primary	53.99 Bn	-17.13	24.23	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	34.48 Bn	44.51	7.18	-
8	BIIB	Biogen Inc.	primary	31.15 Bn	37.32	3.11	8.09 Bn

PolyPid PYPD

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password